Registry following adults with advanced colorectal cancer after two prior treatments
Records treatments and outcomes in adults with spread colorectal cancer after two prior therapies.
Plain-language title generated from the registry record
Registry title: AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
Key facts
- Where
- Linz, Rankweil, Salzburg, Steyr, Wels, and Zams, AustriaSee the 7 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How many different drug treatment plans (such as chemotherapy) have you had for cancer that has spread?
Source: NCT06678919, who can take part
Where in Austria
- KUK Linz - Med Campus III.: Univ.-Klinik für Hämatologie und Internistische OnkologieLinz, AustriaTaking people
- Ordensklinikum Linz, BHS - Interne ILinz, AustriaTaking people
- LKH Feldkirch: Innere Medizin II/ Interne E (Hämatologie und Onkologie)Rankweil, AustriaTaking people
- Department of Internal Medicine III, Paracelsus Medical University SalzburgSalzburg, AustriaTaking people
- Klinikum Steyr: Innere Medizin II: Onkologie, Gastroenterologie, AngiologieSteyr, AustriaTaking people
- Klinikum Wels: Abteilung für Innere Medizin IVWels, AustriaTaking people
- KH Zams: Innere Medizin Internistische Onkologie und HämatologieZams, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Trial code
- NCT06678919
- Record updated
- 10 April 2025
- Original description
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall survival (OS) ranging between 9-38 months depending on various prognostic and predictive factors. Particularly in advanced stages (in the third line of therapy and beyond), interesting and promising results have recently been achieved with various treatment approaches. The aim of this registry is to establish a disease-specific registry to evaluate the treatment landscape of patients with mCRC who have already received at least two lines of therapy.Read full original descriptionShow less
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall survival (OS) ranging between 9-38 months depending on various prognostic and predictive factors. Particularly in advanced stages (in the third line of therapy and beyond), interesting and promising results have recently been achieved with various treatment approaches. The aim of this registry is to establish a disease-specific registry to evaluate the treatment landscape of patients with mCRC who have already received at least two lines of therapy.
Inclusion: patients ≥ 18 years with tissue-based diagnosis of mCRC; ≥ 2 prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (in case of RAS/BRAF wildtype), anti-PD1- therapy (in case of MSI/MMRd) . (Exception: Patients who have received mFOLFOXIRI +/- anti-VEGF or anti- EGFR- 1L therapy or patients with ineligibility to receive 5-FU, oxaliplatin or irinotecan can be included after 1st line.).
Exclusion: Due to the non-interventional design of this registry, there are no specific exclusion criteria.